Cyclins A, B, E and p27 in Endometrial Endometrioid Adenocarcinoma

Santala, Simi; Talvensaari-Mattila, Anne; Soini, Ylermi; Kuvaja, Paula; Santala, Markku

doi:10.21873/anticanres.11245

Cited by 4 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, CA 125 levels of patients in advanced stages were found to be statistically significantly higher than CA 125 levels of patients in early stages (p=0.001). In addition, the fact that CA 125 levels are significantly higher in cases with greater depth of myometrial invasion shows that contrary to some studies, CA 125 levels can be used preoperatively to predict not only lymph node metastasis but also myometrial invasion 14 . Niloff and colleagues 15 These results support our results and suggest that serum CA125 levels can be used as a marker of disease spread in patients diagnosed with EC.…”

Section: Discussionmentioning

confidence: 63%

Investigation of the Role of Preoperative Serum CA 125 Levels in Determining the Necessity of Lymphadenectomy in Cases Diagnosed with Endometrium Cancer: A Retrospective Study

Yoğurtçuoğlu,

KOSE

2023

Adv Res Obstet Gynaecol

View full text Add to dashboard Cite

Objective: The aim of this study is to investigate the relationship between preoperative serum CA 125 levels and clinicopathological parameters in patients operated for endometrial carcinoma (EC) and to reveal the effectiveness of preoperative serum CA 125 levels in determining the necessity of lymphadenectomy. Materials and Methods: The study included retrospective data of 88 patients who underwent surgery due to EC. The relationship between the patients' preoperative serum tumor marker CA-125 levels and tumor grade, stage, histological type, lymph node positivity was evaluated statistically. The statistical significance of CA-125 levels in determining the need for lymph node dissection was analyzed. Results: When the preoperative diagnostic methods of the cases were evaluated according to their surgical stage; the mean CA 125 value was 31.21±35.54 (4.4-150.3) IU/ml in early stage (Stage I-II) patients and 349.13±497.34 (19.5-1566) IU/ml in advanced stage (Stage III-IV) patients (p=0.001). Considering the depth of myometrial invasion and preoperative CA 125 values, the mean preoperative CA 125 values were 21.43±20.06 (4.4-44.1) IU/ml in cases with myometrial invasion less than 1/2, while this value was 141.03±329.47 (6.8-1566) IU/ml in cases with more than 1/2 and the difference between the groups was found to be statistically significant (p=0.025). CA 125 levels of cases with positive lymph nodes were statistically significantly higher than CA 125 levels of cases with negative lymph nodes (p<0.05). While the CA 125 level was 35 IU/ml and above in all cases with positive lymph nodes, the CA 125 level was 35 IU/ml and above in 30.2% of the cases with negative lymph nodes (p<0.05). Conclusions: The results we obtained in this study support the association of increased preoperative CA 125 levels with lymph node positivity, advanced stage and myometrial involvement above ½ in cases with EC.

show abstract

Section: Discussionmentioning

confidence: 63%

Investigation of the Role of Preoperative Serum CA 125 Levels in Determining the Necessity of Lymphadenectomy in Cases Diagnosed with Endometrium Cancer: A Retrospective Study

Yoğurtçuoğlu,

KOSE

2023

Adv Res Obstet Gynaecol

View full text Add to dashboard Cite

show abstract

“…Most studies of CA-125 and EC included patients with advanced-stage disease [8][9][10] . Therefore, CA-125, as an epithelial surface antigen, can be expected to be elevated in patients with advanced-stage disease and may be associated with disease recurrence.…”

Section: Discussionmentioning

confidence: 99%

“…Preoperative cancer antigen-125 (CA-125) levels have also been linked to disease recurrence 7 . While an elevation in serum CA-125 levels has been found to be correlated with advanced-stage EECs, its role in early-stage EECs is still a topic of debate [8][9][10] .…”

Section: Introductionmentioning

confidence: 99%

Preoperative cancer antigen-125 levels as a predictor of recurrence in early-stage endometrial cancer

Erturk,

Korkmaz,

Arslantas

et al. 2024

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

OBJECTIVE: Endometrial cancer is the most common gynecological cancer in developed countries, with a majority of cases being low-grade endometrioid endometrial cancer. Identifying risk factors for disease recurrence and poor prognosis is critical. This study aimed to assess the correlation between preoperative cancer antigen-125 levels and disease recurrence in early-stage endometrioid endometrial cancer patients. METHODS: The study was a retrospective analysis of 217 patients diagnosed with endometrioid endometrial cancer who underwent surgical treatment at a university-affiliated tertiary hospital between 2016 and 2022. Patients were divided into two groups based on their preoperative cancer antigen-125 levels and compared with clinicopathological findings and disease recurrence. Disease-free survival rates were calculated, and logistic regression analysis was performed to determine independent factors affecting disease-free survival. RESULTS: The mean age of patients was 61.59±0.75 years, and the mean follow-up time was 36.95±1.18 months. The mean cancer antigen-125 level was 27.80±37.81 IU/mL. The recurrence rate was significantly higher in the group with elevated cancer antigen-125 levels (p=0.025). Disease-free survival was lower in patients with elevated cancer antigen-125 compared with those with normal levels (p=0.005). Logistic regression analysis revealed that elevated cancer antigen-125 levels were associated with disease recurrence (OR: 3.43, p=0.029). CONCLUSION: The findings of this study suggest that preoperative cancer antigen-125 levels can be used as a predictor of disease recurrence in early-stage endometrioid endometrial cancer patients. cancer antigen-125 levels may be a useful tool for risk stratification and patient management in endometrial cancer.

show abstract

“…3,4 Overexpression of cyclin E has been shown to promote genomic instability by causing DNA replication stress and deregulating the G1 to S transition. [4][5][6][7][8][9][10] WEE1 kinase, which arrests cells in G2/M through inhibition of CDK1/2 to block premature mitotic entry, is essential to prevent massive DNA damage and cell death in cyclin E-overexpressed cells, [11][12][13] which can be reversed by WEE1 kinase inhibition with adavosertib, resulting in mitotic catastrophe and apoptosis induced by unrepaired DNA damage. [13][14][15][16] Laboratory studies showed that cyclin E overexpression was predictive of antitumor response to adavosertib, 17 which provided preclinical proof-of-mechanistic evidence to support the use of cyclin E as a potential biomarker of response to adavosertib.…”

Section: Introductionmentioning

confidence: 99%

Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification

Yao

Yuan

et al. 2023

JCO

View full text Add to dashboard Cite

PURPOSE Preclinical cancer models harboring CCNE1 amplification were more sensitive to adavosertib treatment, a WEE1 kinase inhibitor, than models without amplification. Thus, we conducted this phase II study to assess the antitumor activity of adavosertib in patients with CCNE1-amplified, advanced refractory solid tumors. PATIENTS AND METHODS Patients aged ≥ 18 years with measurable disease and refractory solid tumors harboring CCNE1 amplification, an Eastern Cooperative Oncology Group performance status of 0-1, and adequate organ function were studied. Patients received 300 mg of adavosertib once daily on days 1 through 5 and 8 through 12 of a 21-day cycle. The trial followed Bayesian optimal phase II design. The primary end point was objective response rate (ORR). RESULTS Thirty patients were enrolled. The median follow-up duration was 9.9 months. Eight patients had partial responses (PRs), and three had stable disease (SD) ≥ 6 months, with an ORR of 27% (95% CI, 12 to 46), a SD ≥ 6 months/PR rate of 37% (95% CI, 20 to 56), a median progression-free survival duration of 4.1 months (95% CI, 1.8 to 6.4), and a median overall survival duration of 9.9 months (95% CI, 4.8 to 15). Fourteen patients with epithelial ovarian cancer showed an ORR of 36% (95% CI, 13 to 65) and SD ≥ 6 months/PR of 57% (95% CI, 29 to 82), a median progression-free survival duration of 6.3 months (95% CI, 2.4 to 10.2), and a median overall survival duration of 14.9 months (95% CI, 8.9 to 20.9). Common treatment-related toxicities were GI, hematologic toxicities, and fatigue. CONCLUSION Adavosertib monotherapy demonstrates a manageable toxicity profile and promising clinical activity in refractory solid tumors harboring CCNE1 amplification, especially in epithelial ovarian cancer. Further study of adavosertib, alone or in combination with other therapeutic agents, in CCNE1-amplified epithelial ovarian cancer is warranted.

show abstract

Cyclins A, B, E and p27 in Endometrial Endometrioid Adenocarcinoma

Cited by 4 publications

References 21 publications

Investigation of the Role of Preoperative Serum CA 125 Levels in Determining the Necessity of Lymphadenectomy in Cases Diagnosed with Endometrium Cancer: A Retrospective Study

Investigation of the Role of Preoperative Serum CA 125 Levels in Determining the Necessity of Lymphadenectomy in Cases Diagnosed with Endometrium Cancer: A Retrospective Study

Preoperative cancer antigen-125 levels as a predictor of recurrence in early-stage endometrial cancer

Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification

Contact Info

Product

Resources

About